Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures



Status:Recruiting
Conditions:Neurology, Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:2/28/2019
Start Date:September 21, 2018
End Date:November 2021
Contact:Marc Kamin, MD
Email:mkamin@sklsi.com
Phone:201-421-3830

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug
(AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures. Eligible Subjects will continue to
take their usual AEDs and receive either cenobamate or placebo. Subjects will have a 50%
chance or receiving cenobamate or placebo (sugar pill). Subjects will initially receive 12.5
mg of cenobamate or placebo (study drug) and increase the dose every two weeks until they
reach a target dose of 200 mg. Subjects will take study drug at approximately the same time
in the morning (once a day) with or without food. If tolerability issues arise, dosing can be
changed to evening. Also, once a subject reaches 200 mg of study drug, the dose can be
decreased one time to 150 mg, if necessary. The treatment period is 22 weeks and there is a 3
week follow up period, which includes a one week decrease in study drug to 100 mg prior to
stopping. Subjects who complete may be eligible for an extension study and will not have to
complete the follow up period. Subjects will track their seizure types and frequency in a
diary throughout the study.

This randomized, double-blind, placebo controlled trial is designed to look at safety and
efficacy of cenobamate adjunctive therapy as compared to placebo on PGTC seizures in subject
with idiopathic generalized epilepsy. Subjects will be randomized to receive either
cenobamate or placebo on a 1:1 basis. The study will have three periods, pre-randomization
period where a baseline seizure frequency is established, treatment period and follow up
period. The treatment period consists of a 10 week titration phase where subjects are
titrated slowly until they reach the target dose and a maintenance phase. During the
titration phase, subjects will receive 12.5 mg study drug, followed by 25 mg, 50 mg, 100 mg,
and 150 mg study drug every two weeks. During the maintenance phase, subjects will receive
the target dose of 200 mg study drug. Subjects will take their once daily dose of study drug
at approximately the same in the morning with or without food. If tolerability issues arise,
subjects can switch to evening dosing. There is also an option to down-titrate to 150 mg
study drug, one time only. If tolerability issues continue, subjects may be discontinued.
Upon completion of the maintenance phase, eligible subjects will have an opportunity to
enroll in an open-label safety study. Subjects who discontinue early or do not wish to
participate in this additional study will complete the three week follow up period. Subjects
may receive a one week down titration to 100 mg and return for a follow up visit 2 weeks
later.

Throughout the study, subjects will keep a diary containing the type and frequency of
seizures. This will be the primary efficacy measure.

Inclusion Criteria:

1. Subject is male or female and aged ≥18 years.

2. Written informed consent signed by the subject or legal guardian, prior to entering
the study, in accordance with the International Council for Harmonisation (ICH) Good
Clinical Practice (GCP) guidelines. If the written informed consent is provided by the
legal guardian because the subject is unable to do so, a written or verbal assent from
the subject must also be obtained. As required by country-specific regulations, only
the subject may sign the Informed Consent Form (ICF) in accordance with ICH
guidelines.

3. Female subjects of childbearing potential are willing to use an acceptable form of
birth control

4. Subject has a clinical diagnosis of PGTC seizures (with or without other subtypes of
generalized seizures) in the setting of idiopathic generalized epilepsy.

5. Subject experiences at least 3 PGTC seizures in 12 weeks during the Pre-Randomization
Period.

6. Subject has had a routine electroencephalogram (EEG) within 5 years prior to Visit1
(Screening/Baseline) or during the Pre-Randomization Period with
electroencephalographic features consistent with idiopathic generalized epilepsy;
other concomitant anomalies must be explained by adequate past medical history.

7. Subject has undergone computed tomography (CT) or magnetic resonance imaging (MRI)
within 10 years prior to Visit 1 (Screening/Baseline) or during the Pre-Randomization
Period that ruled out a progressive cause of epilepsy.

8. Subject is currently receiving 1 to a maximum of 3 concomitant AEDs with fixed dosing
regimens for a minimum of 30 days prior to Visit 1 (Screening/Baseline).

1. Benzodiazepines (except diazepam, see Exclusion Criterion No.7) taken at least
once per week during the 30 days prior to Visit 1 (Screening/Baseline) for
epilepsy, anxiety, or sleep disorder will be counted as 1 AED and the dosage must
be continued unchanged throughout the study. Therefore, only a maximum of 2
additional approved AEDs will be allowed. (See Exclusion Criterion No. 10 for
intermittent benzodiazepine rescue parameters.)

2. Subjects receiving felbamate as a concomitant AED must meet the following
criteria: i. Have a 2-year history of felbamate use and a history of a fixed
dosing regimen for a minimum of 60 days prior to Visit 1 (Screening/Baseline).
ii. No prior or known history of hepatotoxicity or hematologic disorder due to
felbamate.

9. Subject with an implanted vagal nerve or deep brain stimulator will be allowed if the
stimulator was implanted at least 5 months prior to Visit 1 (Screening/Baseline) and
the stimulator parameters are not changed for 30 days prior to Visit 1 and for the
duration of the study.

10. Subject taking a ketogenic diet will be allowed as long as the diet has been stable
for at least 3 months prior to Visit 1 (Screening/Baseline) and will remain stable for
the duration of the study.

Exclusion Criteria:

1. Female subjects who are pregnant (or planning to become pregnant during the study),
lactating, or breast-feeding.

2. Subject has a history o f status epilepticus that required hospitalization within 12
months prior to Visit 1 (Screening/Baseline).

3. Subject has PGTC seizure clusters where individual seizures cannot be counted or
classified.

4. Subject has a history of non-epileptic psychogenic seizures.

5. Subject has a concomitant diagnosis of Partial Onset Seizures (POS).

6. Subject has a clinical diagnosis of Lennox-Gastaut syndrome.

7. Subject is currently taking (within the 30 days prior to Visit 1 [Screening/Baseline])
any of the following medications: diazepam (for any reason other than as intermittent
benzodiazepine rescue medication), phenytoin, mephenytoin, fosphenytoin,
phenobarbital, primidone, ethotoin, clopidogrel, fluvoxamine, amitriptyline,
clomipramine, bupropion, methadone, ifosfamide, cyclophosphamide, or efavirenz.

8. Subject has participated in previous cenobamate clinical studies.

9. Subject has a history of vigabatrin use within 5months prior to Visit 1
(Screening/Baseline), or the subject plans to begin treatment with vigabatrin during
the study.

a) A subject with a history of vigabatrin use that ended more than 5 months prior to
Visit1 may be enrolled after documented evidence of no vigabatrin-associated
clinically significant abnormality in an automated visual perimetry test.

10. Subject has a history of intermittent use of rescue benzodiazepines (i.e., 1 to 2
doses over a 24-hour period is considered a 1-time rescue) 4 or more times within the
30 days prior to Visit 1 (Screening/Baseline).

11. Subject has received an investigational drug or device within 30 days prior to Visit 1
(Screening/Baseline).

12. Subject has a history of drug or alcohol dependency or abuse within 2 years prior to
Visit 1 (Screening/Baseline).

13. Subject tests positive, via urine drug screen at Visit 1 (Screening/Baseline), for
illicit drugs (e.g., tetrahydrocannabinol, amphetamines) or for a drug that has not
been prescribed (e.g., certain opiates).

14. Subject has a history of any serious drug-induced hypersensitivity reaction
(including, but not limited to, Stevens Johnson syndrome, toxic epidermal necrolysis,
or DRESS) or any drug-related rash requiring hospitalization.

15. History of AED-associated rash that involved conjunctiva or mucosae.

16. History of more than one non-serious drug-related hypersensitivity reaction that
required discontinuation of the medication.

17. Subject has evidence of clinically significant abnormalities or disease (e.g.,
psychiatric, cardiac, respiratory, gastrointestinal, hepatic [aspartate
aminotransferase (AST) or alanine aminotransferase (ALT) more than 2 times the upper
limit of normal (ULN), or total or direct bilirubin not more than ULN], or renal
disease) that, in the opinion of the Principal Investigator, could affect the
subject's safety or conduct of the study.

18. Presence of congenital short QT syndrome or relevant replicated change in QT/QTc
interval less than 340 msec on ECG.

19. Subject has any significant active Central Nervous System (CNS) infection,
demyelinating disease, degenerative neurologic disease or any CNS disease deemed to be
progressive during the course of the study that may confound the interpretation of the
study results.

20. Subject has a creatinine clearance less than 50 mL/min, as calculated by
Cockcroft-Gault equation.

21. Subject has an absolute neutrophil count less than 1500/µL.

22. Subject has platelet count lower than 80,000/µL in subjects treated with valproate.

23. Subject has a history of positive antibody/antigen test for hepatitis A, hepatitis B,
hepatitis C, or HIV.

24. Subject has any suicidal ideation (with intent with or without a plan) at Visit 1
(Screening/Baseline) or Visit 4 (Randomization) (i.e., answering YES to Question 4
and/or Question 5 on the Suicidal Ideation section of the C-SSRS).

25. Subject has more than 1 lifetime suicide attempt.

26. Subject is a staff member or immediate family member of study staff. Any potential
exception to the inclusion as well as exclusion criteria allowing de minimis
(clinically trivial and meaningless) variations must be approved by the Medical
Monitor.
We found this trial at
28
sites
923 Broadway
Woodmere, New York 11598
?
mi
from
Woodmere, NY
Click here to add this to my saved trials
736 E Bullard Ave
Fresno, California 93710
559-437-9700
?
mi
from
Fresno, CA
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
425 University Blvd.
Indianapolis, Indiana 46202
(317) 274-4591
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1215 Duff Avenue
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Bethesda, Maryland 20817
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
Brooklyn, New York 11215
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
?
mi
from
Budapest,
Click here to add this to my saved trials
Buffalo, New York 14203
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
East Lansing, Michigan 48824
?
mi
from
East Lansing, MI
Click here to add this to my saved trials
?
mi
from
Edison, NJ
Click here to add this to my saved trials
Golden Valley, Minnesota 55422
?
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Honolulu, Hawaii 96817
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Miami, Florida 33176
?
mi
from
Miami, FL
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
1020 Walnut St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19140
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Renton, Washington 98055
?
mi
from
Renton, WA
Click here to add this to my saved trials
Roanoke, Virginia
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
San Diego, California 92093
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Scarborough, Maine 04074
?
mi
from
Scarborough, ME
Click here to add this to my saved trials
?
mi
from
Spokane, WA
Click here to add this to my saved trials